BioPharmSignal logoBioPharmSignal

Biotech News

Pulmonx Reports Second Quarter 2026 Financial Results

Pulmonx (LUNG)PulmonxEarnings

REDWOOD CITY, Calif., July 29, 2026 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2026 ended June 30, 2026.

Related news

LUNGPulmonx2026-10-27 20:05 EST

Pulmonx Reports Third Quarter 2026 Financial Results

LUNGPulmonx2026-10-13 20:05 EST

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

TMCITreace Medical Concepts2026-11-06 12:05 EST

Treace Medical Concepts Reports Third Quarter 2026 Financial Results

CVRXCVRx2026-11-05 21:05 EST

CVRx Reports Third Quarter 2026 Financial and Operating Results

PLSEPulse Biosciences2026-11-05 21:05 EST

Pulse Biosciences Reports Business Updates and Third Quarter 2026 Financial Results

APYXApyx Medical2026-11-05 12:00 EST

Apyx Medical Corporation Reports Third Quarter 2026 Financial Results

SGHTSight Sciences2026-11-04 21:05 EST

Sight Sciences Reports Third Quarter 2026 Financial Results and Raises Full-Year 2026 Revenue Guidance

ADPTAdaptive Biotechnologies2026-11-04 21:05 EST

Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results

PRCTPROCEPT BioRobotics2026-11-04 21:05 EST

PROCEPT BioRobotics Reports Third Quarter 2026 Financial Results and Reaffirms 2026 Financial Guidance

ACHCAcadia Healthcare2026-11-04 21:05 EST

Acadia Healthcare Announces Third Quarter 2026 Results and Raises Full Year 2026 Financial Guidance

View all latest news

Pulmonx

Minimally Invasive COPD Treatment Pulmonx develops minimally invasive technologies for patients with severe emphysema and chronic obstructive pulmonary disease who remain highly symptomatic despite medical therapy. Zephyr Endobronchial Valve The Zephyr Valve is an implantable bronchoscopic device that occludes selected diseased lung...

Recent company news

LUNGPulmonx2026-10-28 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

LUNGPulmonx2026-10-27 20:05 EST

Pulmonx Reports Third Quarter 2026 Financial Results

LUNGPulmonx2026-10-13 20:05 EST

Pulmonx to Report Third Quarter 2026 Financial Results on October 27, 2026

LUNGPulmonx2026-09-01 20:05 EST

Pulmonx Corporation Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LUNGPulmonx2026-08-27 20:05 EST

Pulmonx to Participate in Upcoming Investor Conferences

Stock data

Close
2.56 USD
Market cap
68M USD
Exchange
NASDAQ
Sector
MedTech
Location
United States